Vanguard Capital Management
CORT icon

Vanguard Capital Management’s Corcept Therapeutics CORT Stock Holding History

Vanguard Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$502M Buy
4,353,398
+180,916
+4% +$19.5M 0.01% 680
2026
Q2 		$363M Buy
4,172,482
+95,286
+2% +$5.75M 0.01% 825
2026
Q1 		$164M Buy
+4,077,196
New +$152M ﹤0.01% 1192

Other funds holding CORT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Ingalls & Snyder LLC
Ingalls & Snyder LLC New York $3.91B AUM 60.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Parallel Advisors
Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Capital Management's CORT Position: Q3 2026 in Review

Vanguard Capital Management increased its Corcept Therapeutics (CORT) stake by 4.3% in Q3 2026, buying an estimated $19.5M and bringing the position to 4,353,398 shares worth $502M. The position accounts for 0.01% of the portfolio, ranked #680.

Vanguard Capital Management first reported a position in CORT in Q1 2026 and has held it in 3 quarters since. 403 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Vanguard Capital Management held 4,353,398 shares of Corcept Therapeutics worth $502M as of Q3 2026.
  • Vanguard Capital Management bought 180,916 Corcept Therapeutics shares in Q3 2026, an estimated $19.5M.
  • Corcept Therapeutics made up 0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #680 holding.
  • Vanguard Capital Management first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 403 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.